In the Desulfovibrio species transplantation group of mice, serum and hepatic cholesterol levels were significantly elevated in the transplanted mice (Fig
Among Medicare-eligible adults considering GLP-1 therapy, the highest-risk subgroups for adverse outcomes from inadequately monitored weight loss include: Adults 75 and older, particularly those with pre-existing frailty or recent unintentional weight loss Postmenopausal women with pre-existing osteopenia or osteoporosis who are not on bone-protective therapy Adults with pre-existing sarcopenia identified by prior weakness, gait slowing, or history of falls People with low protein intake due to food insecurity, dental problems, or swallowing difficulties Those taking multiple medications that interact with the cardiovascular effects of rapid weight loss, including antihypertensives and diuretics that may require dose adjustments as weight decreases Symptoms and Warning Signs to Watch For Older adults beginning GLP-1 therapy should watch for and report the following to their prescribing physician promptly: Rapid or unexpected weight loss (more than 1.5 kg or 3.3 lbs per week) Increased weakness, difficulty rising from a chair without arm support, or balance problems Falls or near-falls Reduced grip strength or difficulty with tasks requiring hand strength Poor appetite or inability to meet daily protein targets despite nutritional counseling Any fracture following minimal trauma What You Can Do Now For Medicare beneficiaries considering the GLP-1 Bridge Program: Before starting, ask your physician to assess your current muscle mass and strength
The drug orchestrates an interaction between appetite control and changes in metabolic rate resulting in these variations, in weight
In a healthy gut, your resident bacteria produce SCFAs when they break down fibre
Contraindications and Who Should Avoid Oral GLP-1 Oral semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), as GLP-1 agonists may theoretically increase thyroid C-cell proliferation
